Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6NC8G)

Drug Name

N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide Drug Info

Synonyms

CHEMBL521733; N-(2-(1H-Indol-3-yl)ethyl)biphenyl-4-carboxamide; N-[2-(1H-indol-3-yl)ethyl]biphenyl-4-carboxamide; AC1LG1FS; Oprea1_829316; Oprea1_192683; MolPort-001-987-537; ZINC285233; STK129364; BDBM50272836; AKOS000554028; MCULE-1062167425; NCGC00304458-01; BAS 03049800; ST45172084; AB01300868-01; N-[2-(1H-indol-3-yl)ethyl]-4-phenylbenzamide; N-(2-indol-3-ylethyl)(4-phenylphenyl)carboxamide; Biphenyl-4-carboxylic acid [2-(1H-indol-3-yl)-ethyl]-amide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 787236
TTD Drug ID: DM6NC8G

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cyclin-dependent kinase 4 (CDK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Apremilast	DMTWS9E	Psoriasis vulgaris	EA90	Approved	[2]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[3]
Palbociclib	DMD7L94	Breast cancer	2C60-2C65	Approved	[4]
Ribociclib Succinate	DM9CIUW	Breast cancer	2C60-2C65	Approved	[5]
Trilaciclib	DMP5A4T	Small-cell lung cancer	2C25.Y	Approved	[6]
LEE011	DMMX75K	Breast cancer	2C60-2C65	Phase 3	[7]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[8]
P276-00	DM9DJL2	Mantle cell lymphoma	2A85.5	Phase 2	[9]
P-276	DMMJUHD	Breast cancer	2C60-2C65	Phase 2	[10]
G1T38	DMQO2IT	Breast cancer	2C60-2C65	Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cyclin-dependent kinase 4 (CDK4)	TT0PG8F	CDK4_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Design, synthesis and biological evaluation of new tryptamine and tetrahydro-beta-carboline-based selective inhibitors of CDK4. Bioorg Med Chem. 2008 Aug 15;16(16):7728-39.
2	Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
3	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
7	Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
8	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
9	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
10	Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
11	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)